Mdxhealth Sa  (MDXH)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $3.6500 $-0.08 -2.145%
Day's High: $3.7199 Week Perf: 2.24 %
Day's Low: $ 3.60 30 Day Perf: -11.19 %
Volume (M): 45 52 Wk High: $ 4.64
Volume (M$): $ 163 52 Wk Avg: $3.38
Open: $3.70 52 Wk Low: $2.15

 Market Capitalization (Millions $) 574
 Shares Outstanding (Millions) 157
 Employees -
 Revenues (TTM) (Millions $) 37
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 3

Mdxhealth Sa
MDxHealth SA is a molecular diagnostics company that specializes in the development and commercialization of advanced tests for urologic cancers. The company offers a range of products and services, including urine-based molecular tests for the diagnosis and management of prostate cancer. These tests are designed to provide valuable information to help healthcare professionals make informed decisions about patient treatment options. MDxHealth SA is committed to advancing precision medicine and improving patient outcomes in the field of urology.

   Company Address: Zone Industrielle des Hauts-Sarts Herstal 4040
   Company Phone Number: 812-6979   Stock Exchange / Ticker: NASDAQ MDXH
   MDXH is expected to report next financial results on April 24, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Veracyte Inc

Veracyte Inc Shatters Expectations with Remarkable Revenue Growth in Q4 2023

Veracyte Inc (VCYT) is a company that has recently experienced significant growth in its revenue. In the Dec 31, 2023 report, the company announced a surge in revenue by 22.295% to $98.20 million compared to the similar quarter a year ago. This highlights the company's ability to generate more sales and increase its market share.
However, it is important to note that Veracyte Inc has also seen its deficit expand at $-0.38 per share. It is crucial to analyze the reasons behind this deficit and whether it is a temporary setback or a long-term concern. Sequentially, the company seems to be improving, as its EPS has improved from $-0.41 per share and revenue has advanced by 8.979% from $90.11 million.
During the October to December 31, 2023 financial period, Veracyte Inc realized a net deficit of $-28.293 million, which is larger than the deficit of $-3.844 million a year ago. It is important to dig deeper into the reasons behind this increased deficit and assess whether it is a result of strategic investments or operational inefficiencies.

Caredx Inc

Caredx Inc. Sees Double-Digit Revenue Decline Through Fiscal Year Ending December 31, 2023

The stock market can be a rollercoaster ride for investors, with its ups and downs and constant changes. However, it is important to remember that even in challenging times, there are always opportunities to be found. One company that has recently faced some setbacks is Caredx Inc. Despite reporting a rise in losses for the fourth quarter of 2023, there are several positive factors investors should consider.
In the financial report, Caredx Inc. disclosed a shortfall per share that inched up to $-2.18 from $-0.34. While this may seem concerning at first, it is important to note that this increase is primarily due to weak demand, rather than any fundamental issues with the company itself. It is crucial to analyze the root causes behind such setbacks in order to make informed investment decisions.

Castle Biosciences Inc

Castle Biosciences Inc reports $0.04 million tax charge in Q4 financial results

Castle Biosciences Inc is a medical laboratory company that specializes in providing diagnostic tests and services for the detection and monitoring of various diseases. The company recently reported its financial performance for the October to December 2023 period, revealing positive results and strong growth.
During this period, Castle Biosciences Inc saw a significant improvement in its earnings per share (EPS), with a decrease in loss per share from $-0.76 to $-0.09 compared to the same period the previous year. This improvement in EPS was also evident when comparing to the previous quarter's loss per share of $-0.26. These positive results indicate that the company has been able to reduce its losses and move closer to profitability.

Natera Inc

Natera Inc Sees Strong Growth in Shares and Financial Performance in Recent Fiscal Period

Natera Inc, a global leader in cell-free DNA testing, has recently recorded a solid gain of 5.37% in its shares during the past five trading days. This increase brings the share price to a high of 19.82% during the first quarter of 2024. Additionally, Natera Inc shares have reached their 52-week high.
In terms of financial performance, Natera Inc has shown significant improvement. In the most recent fiscal period, the company reported a decrease in loss per share to $-0.57, compared to $-1.31 a year prior. The earnings per share (EPS) also improved from $-0.95 in the previous reporting season. Furthermore, the revenue jumped by 43.2% to $311.11 million from $217.25 million in the same reporting season a year ago. Sequentially, the revenue improved by 15.952% from $268.31 million.

National Research Corporation

Breaking Down the Financial Success of NRC Health: A Look at Revenue Consolidation and Earnings Growth in Q4 2023

National Research Corporation (NRC Health) recently released its financial results for the fourth quarter and full calendar year of 2023. Despite a decrease in revenue, the company managed to increase its earnings per share (EPS) and net profits. The CEO, Michael Hays, expressed satisfaction with the company's growth in new sales and operating margin. Additionally, the company achieved a new high in its dividend payout ratio during the third quarter of 2023.
Financial Facts:
1. EPS Growth: NRC Health experienced a 34.48% increase in profit per share, reaching $0.36 per share in the most recent fiscal period. This compares to $0.32 per share in the previous reporting period.
2. Revenue Decline: The company's revenue decreased by -0.375% year on year, amounting to $38.00 million in the most recent fiscal period. However, this decline was marginal, as revenue had increased by 0.148% from $37.95 million in the previous reporting period.
3. Net Earnings Growth: NRC Health reported net earnings of $8.858 million in the most recent fiscal period, reflecting a 33.38% increase from $6.641 million reported in the same period a year ago.


Mdxhealth Sa's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com